Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mizuho Medy CoTSE:4595 -0.17%81 EV-to-EBITDA is 4.49 as of Aug. 27, 2026, which is 51% below its 10-year median of 9.13. GuruFocus rates TSE:4595 with a GF Score™ of 81/100 and a GF Value™ of 円1,353.52 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 734 Drug Manufacturers companies, Mizuho Medy Co ranks better than 87.74% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mizuho Medy Co's enterprise value is 円20,474 Mil.
Mizuho Medy Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円4,556 Mil. Therefore, Mizuho Medy Co's EV-to-EBITDA for today is 4.49.
The historical rank and industry rank for Mizuho Medy Co's EV-to-EBITDA or its related term are showing as below:
TSE:4595'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.11 Med: 9.13 Max: 83.7
Current: 4.49
During the past 12 years, the highest EV-to-EBITDA of Mizuho Medy Co was 83.70. The lowest was 1.11. And the median was 9.13.
TSE:4595's EV-to-EBITDA is ranked better than 87.74% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs TSE:4595: 4.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mizuho Medy Co (TSE:4595) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mizuho Medy Co's PE Ratio (TTM) for today is calculated as:
Mizuho Medy Co's share price for today is 円1730.00.
Mizuho Medy Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円170.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Mizuho Medy Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's EV-to-EBITDA falls into.
Mizuho Medy Co's current Enterprise Value is 円20,474 Mil.
Mizuho Medy Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円4,556 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mizuho Medy Co (TSE:4595) has a EV-to-EBITDA of 4.49 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mizuho Medy Co. This is 51% below median its historical median of 9.13. Over the past decade, Mizuho Medy Co's EV-to-EBITDA has ranged from 1.11 to 83.70. According to the industry distribution chart, Mizuho Medy Co ranks #90 out of 734 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Mizuho Medy Co's EV-to-EBITDA too high?
Mizuho Medy Co's current EV-to-EBITDA of 4.49 is 51% below median its 10-year median of 9.13. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 83.70. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Mizuho Medy Co's value of 4.49 is 65.5% below this industry median. Based on the distribution chart, Mizuho Medy Co ranks #90 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mizuho Medy Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #90 out of 734 companies for EV-to-EBITDA. This places Mizuho Medy Co in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.03. Mizuho Medy Co's value of 4.49 is 65.5% below this benchmark. Historically, Mizuho Medy Co's own EV-to-EBITDA has ranged from 1.11 to 83.70 over the past decade. While the company's 10-year median is 9.13 vs. the industry median of 13.03, Mizuho Medy Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mizuho Medy Co's current EV-to-EBITDA of 4.49 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mizuho Medy Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current EV-to-EBITDA is 4.49, which is 51% below median its own 10-year median of 9.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,353.52, compared to a current price of 円1,730.00 — trading 27.8% above its estimated fair value. The current EV-to-EBITDA is 4.49, which is 51% below median its 10-year median of 9.13 and 65.5% below the Drug Manufacturers industry median of 13.03. Mizuho Medy Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current EV-to-EBITDA is 4.49 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,730.00 is trading 27.8% above its estimated GF Value™ of 円1,353.52.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
EV-to-EBITDA: 4.49 (51% below median its 10-year median of 9.13)
GF Value™: 円1,353.52 vs. price of 円1,730.00 (27.8% above fair value)
Industry Position: 65.5% below the Drug Manufacturers median (#90 of 734)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
81GF Score
Get the complete analysis for TSE:4595
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
